
|Articles|August 18, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
Future Immune Checkpoint Strategies
Author(s)James P. Allison, PhD
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Advertisement
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Learn about the history of immunotherapy > >
Articles in this issue
over 11 years ago
A Brief History of Immunotherapyover 11 years ago
Better Biomarker Testing Needed in Immuno-Oncologyover 11 years ago
Autoimmunity and Limitations of Cancer Vaccinesover 11 years ago
The Management of Side Effects Associated With Immunotherapiesover 11 years ago
The Next Wave in Immunotherapy: CombinationsAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5









































